NCT05238207View on ClinicalTrials.gov

A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Hereditary Hemochromatosis
Interventions
DRUG

BBI-001

Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion

DIETARY_SUPPLEMENT

Original Fibre Metamucil

Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion

Trial Locations (1)

3004

Nucleus Networks, Melbourne

Sponsors

Lead Sponsor

Bond Biosciences
All Listed Sponsors
lead

Bond Biosciences

INDUSTRY